Protocol: ECOG – EA5162

Schema – EA5162

Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you!

Eligibility:

1. Participants must have a pathologically-confirmed diagnosis of nonsmall cell lung cancer (NSCLC).
2. Participants must have advanced disease – either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease.
3. An EGFR exon 20 insertion mutation must be detected in the tumor tissue. Patients may be enrolled in the study based on an exon 20 insertion EGFR mutation detected by any CLIA-certified tissue assay.
4. Patients must have measurable disease. Baseline measurements and ALL sites of disease must be obtained within 4 weeks prior to registration.
5. Patients must have previously received at least one line of therapy for their advanced lung cancer. There are no restrictions on the maximum number of prior therapies allowed.Participants must not have previously received osimertinib. Participants must have not previously received therapies targeting PDL1, PD1 or CTLA4 within 6 months (180 days) prior to registration.
6. Age ≥ 18 years.
7. ECOG performance status ≤1.
8. Participants may not have clinically active or symptomatic interstitial lung disease or interstitial pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention), or a history of clinically
   significant interstitial lung disease or radiation pneumonitis.
9. Participants may not have had radiation to the lung fields within four weeks (28 days) of starting treatment. For patients receiving palliative radiation to thoracic vertebrae, ribs or other sites where the radiation field includes the lungs, radiation must be completed at least two weeks before starting treatment. For all palliative radiation to all other sites, at least 7 days must have elapsed prior to starting treatment. At least six months (180 days) must have elapsed prior to starting treatment for radiation given with curative intent. Palliative radiotherapy to control symptoms (including gamma knife technique) is permitted. For stereotactic radiosurgery (SRS) to CNS lesions, osimertinib can be held on the day of radiation only. For palliative RT to other sites of disease outside of the thorax, osi should be held for a minimum of 3 days before radiation and 3 days after RT is completed, but the duration of washout can be adjusted at the
   investigator’s discretion with the approval of the study PI. For thoracic radiation, a 7-10 day washout period before the procedure and one week period after procedure before restarting osimertinib is advised to minimize the risk of pneumonitis. All radiotherapy related toxicities should be managed and ideally resolved before restarting osimertinib. Investigators should consider the radiotherapy when assessing causality if there are any localized AEs following the procedure.

10. Participants may not have clinically symptomatic brain metastases, leptomeningeal disease or spinal cord compression. Patients may be on a stable dose of corticosteroids to control brain metastases if they have been on a stable dose for two weeks (14 days) prior to study treatment and are clinically asymptomatic.

11. Patients must have an ECHO or a nuclear study (MUGA or First Pass) within 4 weeks (28 days) prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF must be ≥ 50% for the patient to be eligible.

12. Participants may not have a second, clinically active, cancer. Patients with second cancers which have been treated with curative intent and/or are currently inactive are allowed.

13. Participants may not be receiving any other investigational agents. Patients previously treated with investigational agents must complete a washout period of at least two weeks or five half-lives, whichever is longer, before starting treatment.

14. Patients with refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption
of AZD9291 (osimertinib) are ineligible.

15. No unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia and grade 2, prior platinum-therapy–related neuropathy.

Protocol: Alliance – A082002

Schema – A082002

Please Note: Below is partial eligibility, for full eligibility requirements, please contact the Genesys Hurley Cancer Institute Research Department at (810)762-8181, (810)762-8079 and/or (810)762-8038. Thank you!

Eligibility:

1. Histologic or cytologic diagnosis of Stage IV NSCLC using version AJCC 8th edition (includes M1a, M1b, and M1c stage disease). Patients with Stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation. PD-L1 IHC: PD-L1 expression Tumor Proportion Score (TPS) <1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a CLIA (or equivalent) certified laboratory. For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known
   actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors.
2. Measurable disease, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for SBRT
3. Age ≥ 18 years.
4. ECOG Performance Status 0-2.
5. No prior systemic chemotherapy or immunotherapy for advanced NSCLC. No prior treatment with checkpoint inhibitors for metastatic lung cancer. Chemotherapy for non-metastatic disease (e.g., adjuvant therapy) or
   immunotherapy for locally advanced Stage III disease is allowed if terminated at least 6 months prior to registration.No systemic immunostimulatory or immunosuppressive drugs, including >10mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. ≥ 1 week since palliative (including CNS) radiotherapy to any tumor site. No prior allogeneic tissue/solid organ transplant.
6. No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study
   requirements. No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
7. No patients with a “currently active” second malignancy that is progressing or has required active treatment within the last 2 years. Participants with nonmelanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinomaor cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible.
8. No hypersensitivity (≥ Grade 3) to immunotherapy and/or any of its
   excipients.

Protocol: ECOG – EA5182

Schema – EA5182

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

Eligibility:

1. Patient must have a pathologically-confirmed diagnosis of nonsquamous, non-small cell lung cancer.
2. Patient must have advanced disease, defined as – either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease.
3. Patient must have somatic activating sensitizing mutation in EGFR (e.g. but not limited to Exon 19 deletion, L858R, E709X, G719X, exon 19 insertions, L861Q, S768I). Patients with non-sensitizing mutations in EGFR (EGFR exon 20 insertions) are not eligible. Test results originating from a CLIA-certified or similarly accredited laboratory are acceptable; no specific assay is mandated. Plasma, cytology, or tumor tissue can be utilized for mutation testing.
4. Patient must not have received any prior treatment with an EGFR TKI or with an anti-VEGF agent.
5. Patients that have received prior radiation therapy are eligible.
6. Patient must have measurable disease.
7. Patient must not have had any prior systemic treatment for metastatic disease.
8. Patient must be ≥ 18 years of age.
9. Patient must have an ECOG Performance status of 0 to 2.
10. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
11. Patient must not have had treatment with any investigational drug within five half-lives or 3 months (whichever is greater), prior to study initiation.
12. Patient must not have any unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of registration, with the exception of alopecia and grade 2 prior platinum-therapy–related neuropathy.
13. Patient must not have mean resting corrected QT interval (QTc) > 470 msec obtained from 3 electrocardiograms (ECGs), using the screening clinic ECG machine derived QTc value (using Bezet’s correction).
14. Patient must not have any clinically important abnormalities in rhythm, conduction or morphology of resting ECG e.g. complete left bundle branch block, third degree heart block and second-degree heart block.
15. Patient must not have any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, electrolyte abnormalities (including: potassium < LLN; magnesium < LLN; calcium < LLN), congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of
    age in first degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes.

Protocol: Alliance – A081801

Schema – A081801

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and (810) 762-8038. Thank you!

Eligibility:

1. Previously registered to A151216
2. Central and/or local testing of EGFR with no EGFR exon 19 deletion of EGFR L858 R mutation (applicable to non-squamous patients only).
3. Central and/or local testing of ALK with no ALK rearrangement (failed testing is considered negative) (applicable to non-squamous patients only).
4. Central and/or local testing of PD-L1 IHC using one of the following assays: DAKO 22C3, DAKO 28-8, EIL3N or SP263. Note: Local testing results of EGFR and ALK by a local CLIA certified laboratory is acceptable. The report must indicate the result as well as the CLIA number of the laboratory that performed the assay. Local result of PD-L1 by DAKO 22C3, Dako 28-8, EIL3N or SP263 are acceptable for enrollment on A081801. Patients with local results for EGFR, ALK and PD-L1 still need to be registered to A151216 and follow all the submissions requirements but do NOT need to wait for the results to proceed to A081801 registration.
5. Completely resected stage IIA, IIB IIIA or IIIB (T3-4N2) NSCLC (squamous or non-squamous) with negative margins. Note: Patients with pathologic N2 disease, completely resected, are eligible. However, patients known to have N2 disease prior to surgery are not eligible; guidelines do not recommend up-front surgery for this population.
6. No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis.
7. No prior allogeneic tissue/solid organ transplant.
8. Age ≥18 years.
9. ECOG PS: 0-1

Protocol: SWOG – S1914

Schema – S1914

Please Note:  Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

Eligibility:

1. Patient must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0). Patient may have
   T3 disease with the exclusion of multifocal tumors and pericardial involvement.
2. Disease must have one or more of the following high-risk features:
   • Tumor diameter ≥ 2 cm as assessed by diagnostic CT
   • Tumor SUV max ≥ 6.2 as assessed by FDG PET/CT
   • Moderately differentiated, poorly differentiated, or undifferentiated histology.
3. Patient must not have evidence of hilar or mediastinal nodal involvement. Any patient with radiographically suspicious hilar or mediastinal nodes (including features such as non-calcified nodes with a short axis diameter > 1 cm, abnormal
   morphology, and/or elevated FDG avidity) must undergo cytologic sampling of suspicious nodes to rule out involvement prior to randomization. Mediastinal nodal sampling for other patients is optional.
4. Patient must be medically or surgically inoperable as documented by a board certified thoracic surgeon or multi-disciplinary tumor board consensus OR patient’s unwillingness to undergo surgical resection must be clearly documented.
5. Patient must not have received any prior treatment for the current NSCLC diagnosis.
6. Patient must not have undergone prior radiation to overlapping regions of the chest that, in the opinion of the treatment physician, will interfere with protocol treatment.
7. Patient must not have received treatment with systemic immunostimulatory or immunosuppressive agents, including corticosteroids, within 14 days prior to randomization.
8. Must be at least 18 years of age.
9. Zubrod Performance Status 0-2.
10. Patients must not have a prior or concurrent malignancy whose natural history or treatment has the potential (in the opinion of the treating physician) to interfere with the safety or efficacy assessment of the investigational regimen.

Protocol: SWOG – S1900E

Schema – S1900E

Please Note:  Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or   (810) 762-8038. Thank you!

Eligibility:  Sub-Study of Lung Map

1. Participants must have confirmed Stage IV or recurrent non-squamous non-small cell lung cancer (NSCLC). Mixed histology NSCLC with less than 50% squamous component is allowed.
2. Participants must have measurable disease. Measurable disease must be assessed within 28 days prior to sub-study registration.
3. Participants must have a CT or MRI scan of the brain to evaluate for CNS disease within 42 days prior to sub-study registration.
4. Participants with EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS1 gene rearrangement, or BRAF V600E mutation must have progressed following all standard of care targeted therapy.
5. Participants must have received at least one line of systemic treatment for Stage IV or recurrent NSCLC.
6. Participants must have progressed (in the opinion of the treating physician) following the most recent line of systemic therapy for NSCLC.
7. Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub study registration.
8. Participants must not have received any radiation therapy within 14 days prior to sub-study registration, with the exception of stereotactic radiation to CNS metastases which must have been completed at least 7 days prior to sub-study
   registration.
9. Participants must not have received prior sotorasib (AMG 510) or other KRASG12C specific inhibitor.
10. Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study.
11. Participants must not have had a major surgery within 14 days prior to sub-study registration.
12. Participants must be able to swallow tablets whole.
13.  Zubrod performance status must be 0-1.
14. Participants must not have a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.

Protocol: ECOG – EA5191

Schema – EA5191

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or    (810) 762-8038. Thank you!

Eligibility:

1. Must be at least 18 years of age.
2. Patient must have pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC).
3. Patient must have Stage IV disease (includes M1a, M1b, or recurrent earlier stage disease), according to the 8th edition of the lung cancer TNM classification system.
4. Patient must have predominant non-squamous histology (patients with NSCLC NOS are eligible). Mixed tumors will be categorized by the predominant cell type. If small cell elements are present the patient is ineligible.
5. Patient’s tumor(s) must be tested and known negative for EGFR TKI sensitizing mutations (EGFR Exon 19 deletions, L858R, L861Q, G719X) and ALK gene rearrangements (by FISH, NGS, or IHC) by routine CLIA-certified clinical testing methods. Negative circulating tumor DNA results alone are not acceptable. Prior testing for tumor PD-L1 status is not required.
6. Patients WITHOUT tumors with known molecular alterations in ROS1, MET, RET (see below), or must have progressed radiographically (per local investigator assessment) following one, but only one, line of platinum-based chemotherapy AND one, but only one, line of prior immunotherapy. Lines of therapy are defined by clinical or radiographic progression. Patients may have received chemotherapy and immunotherapy either concurrently or sequentially in either order. Patient must have received at least 2 prior doses of checkpoint inhibitor therapy in an every 2, 3, or 4 week schedule. No submission of molecular testing is required and patients may be registered for Step 0 then proceed directly to Step 1 screening.  OR  Patients with tumors with known molecular alterations in ROS1, MET, and RETmust have progressed radiographically (per local investigator clinical assessment) on atleast one line of prior chemotherapy or targeted therapy, but there is no limit on number of prior number of therapies. Reciept of prior immunotherapy is allowed but not required.
7. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (in the opinion of the treating physician) are eligible for this trial.
8. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
9. Patients with new or progressive brain metastases (active brain metastases) are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of study treatment.

Protocol: ECOG – EA5181

Schema – EA5181

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

Eligibility:

1. Must be at least 18 years of age.
2. Patient must have one of the following: Newly diagnosed stage IIIA/B/C NSCLC (per the AJCC 8th Edition) that is unresectable and is histologically and/or cytologically confirmed.  Nodal recurrence after surgery for early stage NSCLC.
3. ECOG Performance Status 0-1
4. Body weight > 30 kg of patients.
5. Patient must not have unintentional weight loss > 10% within 30 days prior to registration.
6. Patient must have measurable disease.
7. Patients with nodal recurrence after surgery for early-stage NSCLC are eligible if the following criteria are met: No prior chemotherapy or radiation was ever administered for this lung cancer originally or for recurrence prior to entering this protocol. Prior curative-intent surgery was at least 90 days prior to the nodal recurrence. No prior radiation was administered to the region of study cancer that would cause overlap of treatment fields.
8. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this
   trial. Patients must not have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration.

PROTOCOL: Lung Map

Schema – LungMap

Please Note: Below is partial list of eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

ELIGIBILITY:

Step 0:

1. Patients with adequate archival tissue should be registered directly to Step 1, without registering to Step 0. Patients who need a fresh biopsy to obtain adequate tumor tissue must also submit whole blood for ctDNA testing. These patients must be registered to Step 0 to obtain a patient ID number for the submission.
2. Patients registered to Step 0 are not registered to the LUNGMAP protocol. To participate in LUNGMAP, patients must be registered to Step 1 after evaluation of patient eligibility, including tumor tissue adequacy.

Step 1:

1. Patients must have pathologically proven non-small cell lung cancer (all histologic types) confirmed by tumor biopsy and/or fine-needle aspiration. Disease must be Stage IV or recurrent. All histologies, including mixed, are allowed.
2. Patients must either be eligible to be screened at progression on prior treatment or to be pre-screened prior to progression on current treatment.
3. Screening at progression on prior treatment:
   To be eligible for screening at progression, patients must have received at least one line of systemic therapy for any stage of disease (Stages IIV) and must have progressed during or following their most recent line of therapy.
   1. For patients whose prior systemic therapy was for Stage I-III
      disease only (i.e. patient has not received any treatment for
      Stage IV or recurrent disease), disease progression on platinum based chemotherapy must have occurred within one year from
      the last date that patient received that therapy. For patients treated with consolidation anti-PD-1 or anti-PD-L1 therapy for Stage III disease, disease progression on consolidation anti-PD1 or anti-PD-L1 therapy must have occurred within one year from
      the date of initiation of such therapy.
   2. For patients whose prior therapy was for Stage IV or recurrent disease, the patient must have received at least one line of a
      platinum-based chemotherapy regimen or anti-PD-1/PD-L1 therapy, alone or in combination (e.g. Nivolumab or
      Pembrolizumab).
4. Pre-Screening prior to progression on current treatment:
   To be eligible for pre-screening, current treatment must be for Stage IV or recurrent disease and patient must have received at least one dose of the current regimen. Patients must have previously received or currently be receiving a platinum-based chemotherapy regimen or anti-PD-1/PDL1 therapy, alone or in combination (e.g. Nivolumab or Pembrolizumab). Patients on first-line treatment are eligible upon receiving Cycle 1, Day 1 infusion. Note: Patients will not receive their sub-study assignment until they progress and the LUNGMAP Notice of Progression is submitted.
5. Patients must have adequate tumor tissue available, defined as ≥ 20% tumor cells and ≥ 0.2 mm3 tumor volume.
   • The local interpreting pathologist must review the specimen.
   • The pathologist must sign the LUNGMAP Local Pathology Review Form confirming tissue adequacy prior to Step 1 registration.
6. Patients must agree to have this tissue submitted to Foundation Medicine for common broad platform CLIA biomarker profiling and PD-L1. If archival tumor material is exhausted, then a new fresh tumor biopsy that is formalin-fixed and paraffin-embedded (FFPE) must be obtained. Patients who need the fresh biopsy must also submit whole peripheral blood for ctDNA testing. A tumor block or FFPE slides 4-5 microns thick must be submitted. Bone biopsies are not allowed. If FFPE slides are to be submitted, at least 12
   unstained slides plus an H&E stained slide, or 13 unstained slides must be submitted. However, it is strongly recommended that 20 FFPE slides be submitted. Note: Previous next-generation DNA sequencing (NGS) will be repeated if done outside this study for sub-study assignment.
7. Patients must agree to have any leftover tissue (tissue that remains after biomarker testing) retained for the use of correlative studies outlined in the substudy treatment consents.
8. Patients with known EGFR sensitizing mutations, EGFR T790M mutation, ALK gene fusion, ROS 1 gene rearrangement, or BRAF V600E mutation are not eligible unless they have progressed following all standard of care targeted therapy. EGFR/ALK/ROS/BRAF testing is not required prior to Step 1 registration, as it is included in the Foundation One testing for screening/prescreening.
9. Patients must have Zubrod performance status 0-1.
10. Patients must be ≥ 18 years of age.

PROTOCOL: ECOG-EA5163

Schema – EA5163

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

ELIGIBILITY:

1. Patients must have histologically or cytologically confirmed stage IV non-squamous NSCLC (includes M1a, M1b, and M1c stage disease. Patients with Stage IIIB and IIIC disease are eligible if they are not candidates for combined chemotherapy and radiation.
2. Patients must have PD-L1 expression Tumor Proportion Score (TPS) ≥ 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed, the patients are not eligible. The assay must have been performed by a CLIA (or equivalent) certified laboratory.
3. Patients must have measurable or non-measurable disease.
4. Must be at least 18 years of age.
5. ECOG Performance Status 0-1
6. Prior systemic chemotherapy or immunotherapy for advanced metastatic NSCLC. Patients treated with any prior checkpoint inhibitors for metastatic lung cancer are ineligible. Chemotherapy for non-metastatic disease (e.g.
   adjuvant therapy) or immunotherapy for locally advanced Stage III disease is allowed if at least 6 months have elapsed between the last dose of the prior therapy and study registration. Local therapy, e.g. palliative radiation, is
   allowed as long as a period of 14 days has passed between completion of local therapy and study registration. Registration prior to treatment during the 14 days is allowed. Palliative radiation must be to non-target lesions.
7. Methotrexate (MTX) given in low doses for non-malignant conditions with last dose at least 14 days prior to date of registration will be allowed. Other low dose chemotherapeutics for non-malignant conditions will be considered, but review by the study chair is required.
8. Patients with known EGFR mutations (except exon 20 insertion), BRAF mutations (V600) or ALK or ROS1 translocations that can be treated with oral tyrosine kinase inhibitors are excluded.
9. Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
10. Patients with prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
11. Patients must not receive any other investigational agents during the course of therapy.

PROTOCOL: ECOG-E4512

Schema – E4512

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

ELIGIBILITY:

1. Must be at least 18 years of age.
2. Patients must have undergone complete surgical resection of their stage IIA, IIB, IIIA or IIIB non-squamous or squamous b and have had negative margins. N3 disease is not allowed.
3. ECOG Performance Status 0-1
4. Positive for translocation or inversion events involving the ALK gene locus (e.g. resulting in EML4-ALK fusion) as defined by a CLIA approved test including: (1) translocation or inversion events involving
   the ALK gene locus (e.g. resulting in EML4-ALK fusion) as determined by the Vysis Break Point FISH assay; (2) ALK protein expression by immunohistochemistry (IHC); or (3) ALK rearrangement identified by
   Next Generation (NexGen) sequencing.
5. Patients must have completed any prior adjuvant chemotherapy or radiation therapy 2 or more weeks (6 or more weeks for mitomycin and nitrosoureas) prior to randomization and be adequately recovered at the time of randomization.
6. Patients must not have any history of locally advanced or metastatic cancer requiring systemic therapy within 5 years from randomization, with the exception of in-situ carcinomas and non-melanoma skin cancer. Patients must have no previous primary lung cancer diagnosed concurrently or within the past 2 years.
7. Patients may not be receiving any other investigational agents while on study.

PROTOCOL: Alliance-A151216

Schema – A151216

Please Note: Below is partial eligibility, for full eligibility requirement’s, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!

ELIGIBILITY:

1. For pre-surgical patients:
   1. Suspected diagnosis of resectable non-small cell lung cancer. Cancers with a histology of “adenosquamous” are considered a type of adenocarcinoma and thus a “non-squamous” histology. Patients with squamous cell carcinoma are eligible.
   2. Suspected clinical stage of IIIA, II (IIA or IIB) or large IB (defined as size ≥4cm). Note: IB tumors <4cm are NOT eligible. Stage IB cancer based on pleural invasion is not eligible unless the tumor size is ≥4cm.
2. For post-surgical patients:
   1. Completely resected non-small cell lung cancer with negative margins (R0). Patients with squamous cell carcinoma are eligible only if they have not received adjuvant therapy.
   2. Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size ≥4 cm). Note: IB tumors <4cm are NOT eligible. Stage IB cancer based on pleural invasion is not eligible unless the tumor size is ≥4cm. The 7th edition of AJCC staging will be utilized.
3. ECOG Performance Status 0-1.
4. Age ≥ 18 years.
5. No patients who have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer.
6. No locally advanced or metastatic cancer requiring systemic therapy within 5 years prior to registration. No secondary primary lung cancer diagnosed concurrently or within 2 year prior to registration.
7. No prior treatment with agents targeting EGFR mutation, ALK rearrangement, and PD1/PD-L1/CTLA-4.
8. Patients who have had local genotyping are eligible, regardless of the local result.
9. No patients with recurrence of lung cancer after prior resection.
10. Note: Post-surgical patients should proceed to registration immediately following pre-registration.
11. Tissue available for the required analyses (either clinical tissue block or slides and scrolls.
12. Completely resected NSCLC with negative margins (R0). Cancers with a histology of “adenosquamous” are considered a type of adenocarcinoma and thus a “nonsquamous” histology.
13. Pathologic stage IIIA, IIA or IIB, or large IB (defined as size ≥ 4cm). Note: IB tumors <4cm are NOT eligible. Stage IB cancer based on pleural invasion is not eligible unless the tumor size is ≥4cm.
14. Patients with squamous cell carcinoma are eligible only if they have not received adjuvant therapy.